Vivos Therapeutics Inc. (VVOS) News
Filter VVOS News Items
VVOS News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
VVOS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest VVOS News From Around the Web
Below are the latest news stories about VIVOS THERAPEUTICS INC that investors may wish to consider to help them evaluate VVOS as an investment opportunity.
Best Momentum Stocks to Buy for January 8thVVOS, DXC and YELP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024. |
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesLITTLETON, Colo., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced that it has entered into definitive agreements |
All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to BuyVivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagVivos Therapeutics ( NASDAQ:VVOS ) Third Quarter 2024 Results Key Financial Results Revenue: US$3.86m (up 17% from 3Q... |
Vivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...Vivos Therapeutics Inc (VVOS) reports strong revenue growth and strategic advancements, despite facing increased net losses and market uncertainties. |
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational UpdateRevenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring |
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference CallCall Scheduled for Thursday, November 14, 2024 at 5:00 pm ETLITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its third quarter 2024 financi |
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical AssociationNew Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and ChildrenLITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders, including obstructive sleep apnea (OSA) in adults and children, today announc |
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesLITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe in children), announced today that it has entered into definitive securities purchase agreements with in |
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In ChildrenOn Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children. Recent published studies report up to 10.1 million U.S. children (ages 6-17) are estimated to suffer from pediatric OSA. Vivos’ DNA appliance is non-invasive, safe, comfortable, affordable, and highly effective. It is designed to reduce nighttime snoring and treat moderate to sever |